Adam Rosenberg

Adam has been on our board since 2020 and was CEO of Athenen Therapeutics, which merged into Eliem Therapeutics in 2020. Adam has 20+ years of industry experience in building healthcare companies, and was most recently CEO of Aliada Therapeutics. Adam was previously President, CEO and member of the Board of Directors of Rodin Therapeutics until its acquisition by Alkermes in 2019, and CEO of Sionna Therapeutics, Link Medicine and Teleos Therapeutics. Adam currently serves on the board of multiple venture-backed, private biotechnology companies. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College.